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Pioglitazone is the most widely used thiazolidinedione and acts as an insulin-sensitizer
through activation of the Peroxisome Proliferator-Activated Receptor-γ (PPARγ).
Pioglitazone is approved for use in the management of type 2 diabetes mellitus (T2DM),
but its use in other therapeutic areas is increasing due to pleiotropic effects. In this
hypothesis article, the current clinical evidence on pioglitazone pharmacogenomics is
summarized and related to variability in pioglitazone response. How genetic variation in
the human genome affects the pharmacokinetics and pharmacodynamics of pioglitazone
was examined. For pharmacodynamic effects, hypoglycemic and anti-atherosclerotic
effects, risks of fracture or edema, and the increase in body mass index in response to
pioglitazone based on genotype were examined. The genes CYP2C8 and PPARG are the
most extensively studied to date and selected polymorphisms contribute to respective
variability in pioglitazone pharmacokinetics and pharmacodynamics. We hypothesized that
genetic variation in pioglitazone pathway genes contributes meaningfully to the clinically
observed variability in drug response. To test the hypothesis that genetic variation in
PPARG associates with variability in pioglitazone response, we conducted a meta-analysis
to synthesize the currently available data on the PPARG p.Pro12Ala polymorphism. The
results showed that PPARG 12Ala carriers had a more favorable change in fasting
blood glucose from baseline as compared to patients with the wild-type Pro12Pro
genotype (p = 0.018). Unfortunately, findings for many other genes lack replication
in independent cohorts to confirm association; further studies are needed. Also, the
biological functionality of these polymorphisms is unknown. Based on current evidence,
we propose that pharmacogenomics may provide an important tool to individualize
pioglitazone therapy and better optimize therapy in patients with T2DM or other conditions
for which pioglitazone is being used.
Keywords: pioglitazone, thiazolidinedione, CYP2C8, cytochrome P450, PPAR, pharmacokinetics,
pharmacodynamics
INTRODUCTION
Pioglitazone (PIO) is the most widely used thiazolidinedione
(TZD) anti-diabetic drug. The first TZD, troglitazone, was
approved for clinical use by the United States Food and
Drug Administration (FDA) in 1997 (Kung and Henry, 2012).
Abbreviations: ACE, angiotensin-converting enzyme; ADIPOQ, adiponectin;
ADIPOR, Adiponectin receptor; ADORA1, adenosine A1 receptor; ADR,
adverse drug reaction; APOH, apolipoprotein H; AUC, area under the plasma
concentration-time curve; BMI, body mass index; CCL2, chemokine C-C motif
ligand 2; CHF, congestive heart failure; CYP, cytochrome P450; FDA, Food and
Drug Administration; FG, fasting plasma glucose; GHRH, growth hormone releas-
ing hormone; GYS1, glycogen synthase 1; IL-6, interleukin-6; IMT, intima-media
thickness; LPL, lipoprotein lipase; MTHFR, methylene-tetrahydrofolate reduc-
tase; NPY, neuropeptide Y; OATP, organic anion transporter family member;
OLR1, oxidized low density lipoprotein receptor 1; PD, pharmacodynamics; PIO,
pioglitazone; PK, pharmacokinetics; PKM2, pyruvate kinase; PPARγ, peroxisome
proliferator-activated receptor γ; PPRE, peroxisome proliferator response ele-
ments; PTPRD, protein tyrosine phosphatase receptor type D; RETN, resistin;
ROSI, rosiglitazone; SLCO, solute carrier organic anion transporter family mem-
ber; SNP, single nucleotide polymorphism; TNFα, Tumor necrosis factor α; TZD,
thiazolidinedione; T2DM, type 2 diabetes mellitus; UCP2, uncoupling protein 2.
However, troglitazone was withdrawn from the market due to
hepatotoxicity and is not currently available (Kung and Henry,
2012). PIO and rosiglitazone (ROSI) were approved by the FDA
in 1999 (Kung and Henry, 2012). Unfortunately, due to an appar-
ent increase in risk of myocardial infarction, ROSI was withdrawn
from the European market in 2010; the FDA restricted the use
of ROSI in the United States in 2011 (Kung and Henry, 2012).
Therefore, PIO is currently the only TZD available without regu-
latory restrictions.
The exact mechanism of action of TZDs remains unclear,
but the current consensus is that TZDs target the transcription
factor peroxisome proliferator-activated receptor-γ (PPARγ) to
improve insulin sensitivity (Cariou et al., 2012; Yau et al., 2013).
Ligand-dependent transactivation of PPARγ causes heterodimer-
ization with the retinoid-X receptor followed by recognition of
peroxisome proliferator response elements (PPREs) that stim-
ulate transcription of genes involved in metabolic homeostasis
(Cariou et al., 2012). Additionally, PPARγ represses transcription
of genes related to inflammation via transrepression, which does
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not require binding to PPREs but antagonizes other transcription
factors that activate inflammatory pathways, such as NF-κB and
AP-1 (Cariou et al., 2012).
PIO was approved for the management of type 2 diabetes mel-
litus (T2DM) (Cariou et al., 2012; Yau et al., 2013). The efficacy
of PIO as an anti-hyperglycemic agent was demonstrated in ran-
domized controlled trials (Cariou et al., 2012). PIO monotherapy
was shown to lower A1C by ∼1% in T2DM patients (Yau et al.,
2013). An advantage of PIO over sulfonylureas and insulin is that
comparable A1C reduction is achieved without significant hypo-
glycemia (Yau et al., 2013). TZDs also improve insulin sensitivity,
whichmay reduce insulin dose or eliminate the need for insulin in
some patients (Yau et al., 2013). In addition to T2DM, PIO use has
increased in other therapeutic areas such as non-alcoholic fatty
liver disease, atherosclerosis, inflammation, infertility, and cancer
due to the wide spectrum of effects secondary to PPARγ activa-
tion (Cariou et al., 2012; Yau et al., 2013). At the same time, more
undesirable off-target effects have been identified. The use of PIO
is typically limited by adverse drug reactions (ADRs) including
bone fractures, peripheral edema, congestive heart failure (CHF),
weight gain, and possible risk of bladder cancer (Cariou et al.,
2012; Yau et al., 2013).
Asmore benefits and risks of PIO have been reported, clinically
relevant variability in response has also been noted (Umpierrez
and Dagogo-Jack, 2006; Yau et al., 2013). However, the sources
of variability in response to PIO are not fully understood. In
this article, we will address the question whether pharmacoge-
nomics contributes to the observed variability in pioglitazone
response. First, the current evidence on genetic variation in
pioglitazone pathway genes will be summarized. Then, current
evidence on genetic variation in the gene encoding the PPARγ
receptor (PPARG) will be evaluated; because the data with PPARG
are inconsistent, we conducted a meta-analysis to estimate the
association between the best studied PPARG polymorphism and
pioglitazone response. Finally, future research directions and
methods to incorporate current pharmacogenomic findings in
clinical practice are proposed.
METHODS
LITERATURE SEARCH
Two databases were used to identify pharmacogenomics evi-
dence: PubMed and Web of Science. The searches were con-
ducted through April 30, 2013. Two searches were performed
with PubMed by using the following terms: (1) (“thiazolidine-
diones”[MeSHTerms] OR “thiazolidinediones”[All Fields]) AND
(“pharmacogenetics”[MeSH Terms] OR “pharmacogenetics”[All
Fields]) and (2) (“thiazolidinediones”[MeSH Terms] OR “thiazo-
lidinediones”[All Fields]) AND (“polymorphism, genetic”[MeSH
Terms] OR (“polymorphism”[All Fields] AND “genetic”[All
Fields]) OR “genetic polymorphism”[All Fields] OR “polymor-
phism”[All Fields]). The numbers of articles found from the two
searches were 33 and 91, respectively without any restrictions.
The following searches were conducted with Web of Science:
Topic = (pioglitazone) AND [Topic = (pharmacogenomics) OR
Topic = (pharmacogenetics) OR Topic = (polymorphism)]. The
original hit number was 84. The titles and abstracts were screened
to include only clinical studies that investigated differences in
PK or PD of PIO based on genetic polymorphisms in human
participants. Articles only written in English were examined and
meeting abstracts were not included in the summary. Sixteen full-
text original research articles meeting our criteria and published
in peer-reviewed journals were identified by our literature search.
META-ANALYSIS
A meta-analysis was conducted with five identified studies
examining the PPARG p.Pro12Ala polymorphism. The change
in fasting plasma glucose (FG) from baseline was used as
the primary outcome of interest because the definition of
the responder phenotype was not consistent between stud-
ies. The data presented in the original articles were used.
For the study by Bluher et al. (2003), the values were not
available in the published article, so they were obtained
directly from the authors [p.Pro12Pro −3.01 ± 3.53mmol/L vs.
p.Pro12Ala −2.98 ± 3.16mmol/L (mean ± standard deviation)].
Units were converted from mmol/L to mg/dL to analyze changes
in FG consistently among studies. Standard differences in means
were used to compare the outcome of interest between the
PPARG p.Pro12Pro genotype and 12Ala carriers by using the
Comprehensive Meta-Analysis V2 program (Biostat, Englewood,
NJ, USA). A test for heterogeneity (I2 = 48.7; p = 0.10) was con-
ducted, and a fixed-effects model was used. The publication bias
was checked (Supplemental figure 1).
RESULTS/DISCUSSIONS
EFFECTS OF GENETIC VARIATION ON PIO PHARMACOKINETICS
Table 1 summarizes clinical studies that investigated the effect
of genetic polymorphisms on PIO pharmacokinetics. The pri-
mary metabolites of PIO are designated as M-I, M-II, M-IV,
M-V, and M-VI (Eckland and Danhof, 2000) (Figure 1). M-IV
is further metabolized to M-III and M-VI may also be formed
from M-V (Eckland and Danhof, 2000). M-IV and M-III are
known to be the major active metabolites and are responsible for
the extended hypoglycemic effect (Eckland and Danhof, 2000).
Multiple cytochrome P450 (CYP) enzymes are involved in the
metabolism of PIO. However, CYP2C8 and CYP3A4 are the most
important enzymes and contribute to ∼60% and less than 20%
of total PIOmetabolism, respectively (Eckland and Danhof, 2000;
Scheen, 2007; Vandenbrink et al., 2011).
Two clinical studies examined genotypes of CYP2C8, the
gene coding for the CYP2C8 enzyme. Both studies showed
that compared to ∗1 homozygotes, the ∗3 variant allele car-
riers had ∼30% lower total systemic exposure to PIO mea-
sured as the area under the plasma concentration-time curve
(AUC) (Tornio et al., 2008; Aquilante et al., 2013). CYP2C8∗3
is the best studied functional polymorphism in this gene. The
∗3 allele is designated by the presence of two non-synonymous
polymorphisms, rs11572080:G>A in exon 3 (p.Arg139Lys) and
rs10509681:A>G in exon 8 (p.Lys399Arg) (Aquilante et al., 2013).
The functional relevance of these polymorphisms appears to be
substrate-dependent. For example, metabolism of PIO, ROSI, and
repaglinide was increased, but metabolism of R-ibuprofen was
decreased in carriers of theCYP2C8∗3 allele (Martinez et al., 2005;
Daily and Aquilante, 2009; Aquilante et al., 2013). The substrate
selectivity of the enzyme is likely due to the amino acid changes in
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Table 1 | Effect of genetic polymorphisms on pioglitazone pharmacokinetics.
Study PIO
(single dose)
Study
population
Gene/
polymorphism
Outcome Results
Aquilante et al.,
2013
PIO 15mg •30 healthy
Caucasians
CYP2C8
•*1/*1: n = 15
•*1/*3: n = 14
•*3/*3: n = 1
AUC0−∞ •*1/*1: 6770 ± 2480 ng*h/mL
•*3 carriers: 4760 ± 2900 ng*h/mL
•*3 carriers had 29.7% lower AUC0−∞
(p = 0.01) than *1 homozygotes
AUC0−∞ with gemfibrozil
(CYP2C8 inhibitor)
600mg BID × 4 days
•*1/*1: 21.100 ± 78.0 ng*h/mL
•*3 carriers: 222.0 ± 99.0 ng*h/mL
•AUC0−∞ increased with gemfibrozil by
5.2-fold in *3 carriers vs. 3.3-fold increase
in *1 homozygotes (p = 0.02)
Tornio et al.,
2008
PIO 15mg •16 healthy
volunteers
CYP2C8
•*1/*1: n = 8
•*1/*3: n = 5
•*3/*3: n = 3
AUC0−∞
(weight-adjusted to
70 kg)
•*1/*1: 4.95 ± 0.96mg*h/L
•*1/*3: 3.67 ± 0.92mg*h/L; 26% smaller
than *1/*1 (p < 0.05)
•*3/*3: 3.25 ± 0.87mg*h/L; 34% smaller
than *1/*1 (p < 0.05)
AUC0−∞
(weight-adjusted to
70 kg) with trimethoprim
(CYP2C8 inhibitor)
160mg BID × 6 days
•*1/*1: 6.60 ± 1.47mg*h/L
•*1/*3: 5.70 ± 1.62mg*h/L
•*3/*3: 4.45 ± 0.46mg*h/L (p < 0.05 vs.
*1/*1)
•% change from PIO alone was *1/*1
133%, *1/*3 155%, and *3/*3 137%
(p = 0.017 between genotypes)
Kalliokoski et al.,
2008
PIO 15mg •32 healthy
Caucasians
SLCO1B1
c.521T > C
•TT: n = 16
•TC: n = 12
•CC: n = 4
AUC0−∞
(weight-adjusted to
70 kg)
•TT: 6422 ± 2050 ng*h/mL
•TC: 4922 ± 1062 ng*h/mL
•CC: 5384 ± 1469 ng*h/mL
•No significant effect on PK of PIO or the
metabolites (M-III, M-IV, and M-V)
TZD, thiazolidinedione; PIO, pioglitazone; AUC, area under the concentration-time curve; BID, twice daily; PK, pharmacokinetics; kg, kilograms.
FIGURE 1 | Abbreviated Pioglitazone Metabolism Pathway. CYP2C8 is
the major enzyme metabolizing pioglitazone and is shown in bold. Enzymes
in the parenthesis are suggested to be involved in pioglitazone metabolism,
but their roles in the formation of particular metabolites are not clear
according to currently available data (Eckland and Danhof, 2000; Jaakkola
et al., 2006; Lai et al., 2009).
the protein structure caused by the polymorphisms. According to
a recent population pharmacokinetic model, the oral clearance of
PIO was∼52% higher in CYP2C8∗3 carriers (Kadam et al., 2013).
Considering that 10–23% of Caucasians carry the ∗3 allele and
that PIO exposure is decreased in carriers (Aquilante et al., 2013),
this genotype is expected to explain some of the variability in
response to PIO therapy. CYP2C8∗3 is most frequently observed
among Caucasians, followed by Hispanics, and the ∗3 variant is
rare among people with African and Asian ancestry (Aquilante
et al., 2013; Martis et al., 2013).
The clinical studies also examined the influence of CYP2C8∗3
on the magnitude of drug-drug interactions. Gemfibrozil was
administered as a CYP2C8 inhibitor and demonstrated that the
resulting increase in AUC was significantly greater in ∗3 carriers
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(5.2-fold) compared with ∗1 homozygotes (3.3-fold) (Aquilante
et al., 2013). This resulted in PIO exposure after inhibition being
similar in the two genotype groups (Aquilante et al., 2013).
When trimethoprim was administered as a CYP2C8 inhibitor,
the increase in AUC was larger in ∗3 carriers, leading to a non-
significant difference in the PIO exposure between ∗1 homozy-
gotes and ∗1/∗3 heterozygotes after the inhibition (Tornio et al.,
2008). A similar genotype-dependent effect on the magnitude
of drug-drug interaction has been reported with other CYP
enzymes, such as CYP2C9, whereby the magnitude of interac-
tion is greater in the individuals having the genotype associated
with higher activity or clearance (Castellan et al., 2013). If a ther-
apy known to inhibit CYP2C8 is initiated in patients with the ∗3
allele taking PIO, close monitoring of PIO therapy is warranted
because the inhibition may be more pronounced in this patient
population.
The effect of genetic variation in the gene that encodes the
organic anion-transporting poly-peptide OATP1B1 (SLCO1B1,
Solute carrier organic anion transporter family member 1B1)
has also been studied. OATP1B1 is an uptake transporter located
at the basolateral membrane of hepatocytes that facilitates drug
entry into the hepatocyte (Zamek-Gliszczynski et al., 2012). PIO
is a substrate and potent competitive inhibitor of OATP1B1
(Kalliokoski et al., 2008). However, no significant effect of
SLCO1B1 polymorphisms on the PK of PIO and its metabolites
(M-III, M-IV, and M-V) was observed (Kalliokoski et al., 2008).
Because the results have not yet been replicated, transporter
polymorphisms should be further studied with PIO.
EFFECTS OF GENETIC VARIATION ON PIO PHARMACODYNAMICS
Table 2 summarizes studies that examined the extent to which
genetic polymorphisms affect PIO pharmacodynamics.
Hypoglycemic effect
The most well-studied polymorphism with respect to PIO
response is PPARG p.Pro12Ala (rs1801282). PPARG is the gene
encoding PPARγ, a ligand-activated transcription factor that reg-
ulates glucose homeostasis (Auwerx, 1999). The minor allele
frequency for this polymorphism has been reported as 2–18% in
healthy humans (Saraf et al., 2012). The 12Ala allele appears to
improve insulin sensitivity due to an alteration in the transcrip-
tional activity of PPARγ (Deeb et al., 1998; Saraf et al., 2012).
This variant has been consistently associated with decreased risk
of T2DM in previous studies (Altshuler et al., 2000). According to
a meta-analysis, the odds ratio of T2DM risk was 0.86 (95% con-
fidence interval 0.81–0.90) with the presence of the 12Ala allele
(Gouda et al., 2010).
PPARγ is the drug target of TZDs, thus it would be bio-
logically plausible for the functional p.Pro12Ala polymorphism
in the PPARG gene to be associated with response to TZDs.
Previously, in response to ROSI, PPARG p.Pro12Ala allele carri-
ers achieved greater reduction in FG (50.6 ± 27.8 vs. 24.3 ± 41.9
mg/dL, p = 0.026) and in A1C (1.41 ± 1.47% vs. 0.57 ± 1.16%,
p = 0.015) than patients without the variant allele (Kang et al.,
2005).
Our search identified five pharmacogenetic studies in which
the effect of PPARG p.Pro12Ala polymorphism on PIO
pharmacodynamic response was examined. The results were not
entirely consistent across studies. Three out of five studies demon-
strated a better response in terms of improvements in FG and
A1C in carriers of the 12Ala allele (Ramirez-Salazar et al., 2008;
Hsieh et al., 2010; Pei et al., 2013). However, two studies reported
a non-significant response to PIO (Bluher et al., 2003; Namvaran
et al., 2011). It is difficult to explain exactly why the results
were disparate, but possible reasons include the heterogeneity of
the studies and small sample sizes of patients with the minor
allele. The studies were quite heterogeneous with respect to the
patient population, the inclusion/exclusion criteria, PIO treat-
ment regimen, and the presence of other anti-diabetic treatments.
In addition, the two negative studies had a relatively small num-
ber of patients with the 12Ala minor allele, suggesting power may
not have been adequate to detect a difference. Although the results
are conflicting, the PPARG p.Pro12Ala polymorphism may con-
tribute to the variability observed in response to PIO as shown
in the three favorable studies. Indeed, according to our meta-
analysis of the five studies identified, PPARG 12Ala allele carriers
had a more favorable change in FG compared to people with
the p.Pro12Pro genotype (p = 0.018, Figure 2). However, this
polymorphism alone does not fully explain why some patients
failed to respond to PIO. Other genetic and environmental fac-
tors are likely to be involved and may have contributed to the
negative results in the two studies. Thus, consideration of other
genes appears important to better explain the variability in PIO
treatment response.
In addition to the PPARG gene, protein tyrosine phosphatase
receptor type D (PTPRD) gene was investigated. PTPRD poly-
morphisms associated with T2DM in a genome wide association
study in a ChineseHan population (Tsai et al., 2010). Rs17584499,
located in intron 10, was the single nucleotide polymorphism
(SNP) with the strongest association (Tsai et al., 2010). The
functionality of this polymorphism has not yet been identified.
Considering that it is located in an intron, the polymorphismmay
affect mRNA splicing or may be in linkage disequilibrium with
other functional polymorphisms. One study found that patients
with rs17584499 wild-type CC genotype had better postpran-
dial plasma glucose concentrations after being treated with PIO
for 3 months compared with T minor allele carriers (Pei et al.,
2013). Confirmation of these results is needed in an independent
cohort. However, it is clear that more polymorphisms remain to
be uncovered to better explain the variability in PIO response.
Such polymorphisms may be identified through populations that
have been previously under-represented.
The adiponectin (ADIPOQ) gene has been studied in patients
receiving PIO therapy. Adiponectin is an adipokine, a peptide
hormone secreted from adipocytes, known to play an important
role in insulin sensitization and fat β-oxidation (Li et al., 2008;
Ruscica et al., 2012). T2DM and insulin resistance have been
associated with low serum adiponectin levels (Li et al., 2008).
Multiple polymorphisms in ADIPOQ associated with T2DM in
various ethnic populations, including Asians and Caucasians with
European ancestry (Hara et al., 2002; Menzaghi et al., 2002;
Stumvoll et al., 2002; Vasseur et al., 2002, 2003; Vozarova De
Courten et al., 2005; Woo et al., 2006; Li et al., 2008; Jing et al.,
2012).
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Table 2 | Effect of genetic polymorphisms on pioglitazone pharmacodynamics.
Study TZD
regimen
Study population
(inclusion criteria)
Gene/
polymorphism
Outcome Results
Bluher et al.,
2003
PIO 45mg
QD for >26
weeks
•131 patients with T2DM
•A1C = 7.5–11.5%
•FG = 7.8–14.0mmol/L
•BMI = 25–35 kg/m2
•No other antidiabetic
medications
PPARG Pro12Ala
•p.Pro12Pro =
110
•p.Pro12Ala = 16
•p.Ala12Ala = 5
>20% decrease in
FG
•p.Pro12Pro: OR 0.45; p = 0.67
•p.Pro12Ala: OR 0.78; p = 0.31
•p.Ala12Ala: OR 0.61; p = 0.76
15% decrease in
A1C
•p.Pro12Pro: OR 0.66; p = 0.23
•p.Pro12Ala: OR 0.42; p = 0.2
•p.Ala12Ala: OR 0.48; p = 0.61
Ramirez-Salazar
et al., 2008
PIO 45mg
QD for 15
days
•77 obese menopausal
women in Mexico
•BMI >30 kg/m2
PPARG Pro12Ala
•p.Pro12Pro = 59
•p.Pro12Ala = 18
Change in FG •p.Pro12Pro: −7 ± 8mg/dL
•p.Pro12Ala: −15 ± 15mg/dL
•p < 0.003
HOMA-IR •p.Pro12Pro: −1 (−2.5 to 0.07)
•p.Pro12Ala: −0.08 (−0.68 to 1.05)
•p < 0.03, mean (25th–75th quartiles)
Hsieh et al.,
2010
PIO 30mg
QD for 24
weeks
•250 Chinese patients
with T2DM
•A1C = 7–11%
•FG = 130–250 mg/dL
•BMI = 25–35 kg/m2
•No change in
medications in the
previous 3 months
PPARG Pro12Ala
•p.Pro12Pro =
197
•p.Pro12Ala = 53
15% decrease in
A1C or 20%
decrease in FG
•p.Pro12Pro: 57.9%
•p.Pro12Ala: 75.5%
•OR 2.39; 95% CI 1.13–5.03; p = 0.022
PPARGC1A
p.Gly482Ser
•p.Gly482Gly =
51
•p.Gly482Ser =
199
15% decrease in
A1C or 20%
decrease in FG
•p.Gly482Gly: 58.8%
•p.Gly482Ser: 62.3%
•OR 1.17; 95% CI 0.58–2.36; p = 0.66
Namvaran et al.,
2011
PIO 15mg
QD for 12
weeks
•101 Iranian patients with
T2DM
•No change in previous
medications
PPARG
p.Pro12Ala
•p.Pro12Pro = 95
•p.Pro12Ala = 6
15% decrease in
A1C
•p.Pro12Pro: 31.6%
•p.Pro12Ala: 33.3%
•NS
Pei et al., 2013 PIO 30mg
QD for 3
months
•67 Chinese patients
with T2DM
•BMI = 19–30 kg/m2
•No other insulin
secretagogue
•No change in
medications in the
previous 3 months
•CYP2C8 *1/*1 genotype
PPARG
rs1801282
(p.Pro12Ala)
•CC = 60
•CG = 7
Change in FG •CC: −1.23 ± 0.48mmol/L
•CG: −2.24 ± 8.2mmol/L
•P < 0.05
PTPRD
rs17584499
•CC = 45
•CT + TT = 22
Change in PPG •CC: −3.18 ± 3.37mmol/L
•CT + TT: −0.63 ± 3.26mmol/L
•P < 0.01
Li et al., 2008 PIO 30mg
QD × 10
weeks
•113 Chinese patients
with T2DM
•A1C >7%
•FG >7mmol/L
•No change in previous
medications
ADIPOQ
C-11377G
•CC = 58
•CG + GG = 55
Change in FG •CC: −0.22 ± 0.16mmol/L
•CG + GG: −0.26 ± 0.19mmol/L
•p = 0.201
Change in A1C •CC: −0.08 ± 0.11%
•CG + GG: −0.13 ± 0.13%
•P = 0.028
ADIPOQ
G-10068A
•GG = 65
•GA + AA = 48
Change in FG •GG: −0.25 ± 0.15mmol/L
•GA + AA: −0.23 ± 0.21mmol/L
•p = 0.593
Change in A1C •GG: −0.11 ± 0.12%
•GA + AA: −0.10 ± 0.12%
•p = 0.811
ADIPOQ A-4041C
•AA = 48
•AC + CC = 25
Change in FG •AA: −0.25 ± 0.17mmol/L
•AC + CC: −0.25 ± 0.19mmol/L
•p = 0.792
(Continued)
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Table 2 | Continued
Study TZD
regimen
Study population
(inclusion criteria)
Gene/
polymorphism
Outcome Results
Change in A1C •AA: −0.12 ± 0.11%
•AC + CC: −0.11 ± 0.10%
•p = 0.398
ADIPOQ T45G
•TT = 65
•TG + GG = 48
Change in FG •TT: −0.23 ± 0.20mmol/L
•TG + GG: −0.25 ± 0.16mmol/L
•p = 0.585
Change in A1C •TT: −0.11 ± 0.13%
•TG + GG: −0.10 ± 0.10%
•p = 0.925
Namvaran et al.,
2012
PIO 15mg
QD × 12
weeks
•101 Iranian patients with
T2DM
•A1C >7%
•FG >7mmol/L
•No change in
medications in the
previous 3 months
ADIPOQ T45G
(rs2241766)
•TT = 66%
•TG = 31%
•GG = 3%
15% decrease in
A1C
•TT: 34.3%
•TG + GG: 26.5%
•OR 1.85; 95% CI 0.72–4.76; p = 0.20
ADIPOR2 G795A
(rs16928751)
•GG = 70%
•GA = 20%
•AA = 10%
15% decrease in
A1C
•GG: 29.6%
•AG: 45%
•AA: 20%
•OR 0.97; 95% CI 0.38-2.50; p = 0.97
Makino et al.,
2009
PIO 15mg
QD × 4
weeks
followed by
30mg × 8
weeks (or
PIO 30mg
× 12 weeks)
•121 Japanese patients
with T2DM and 63
patients in the replication
cohort
•A1C 6.5–12%
•BMI = 16–35 kg/m2
•No change in
medications in the
previous 3 months
RETN C-420G
(rs1862513)
•CC = 55
•CG = 54
•GG = 12
Replication
cohort:
•CC = 30
•CG = 27
•GG = 6
Change in FG •CC: −31.1 ± 33.2 mg/dL
•CG: −37.3 ± 32.8mg/dL
•GG: −54.1 ± 34.6mg/dL
•p = 0.116
Regression coefficient
•CG: −4.80 ± 6.38 mg/dL(p = 0.453,
vs. CC)
•GG: −24.7 ± 10.6 mg/dL (p = 0.021,
vs. CC)
Change in A1C •CC: −0.9 ± 0.8%
•CG: −0.8 ± 0.7%
•GG: −0.9 ± 0.7%
•p = 0.832
Replication cohort:
•CC: −1.3 ± 1.0%
•CG: −1.2 ± 1.3%
•GG: −2.7 ± 2.3%
•p = 0.033
Wang et al.,
2007
PIO 30mg
× 10 weeks
•113 Chinese patients
with T2DM
•A1C =7–12%
•FG ≤16.9mmol/L
•Other
anti-hyperglycemic
agents were allowed (no
change in the previous 3
months)
LPL S447X
•SS 86.73%
•SX 12.39%
•XX 0.88%
•MAF = 7.08%
>10% decrease in
FG
•SS 84%, non-SS 60%
•OR 0.54; 95% CI 0.30–0.97; p = 0.04
>1% decrease in
A1C
•SS 57%, non-SS 27%
•OR 0.74; 95% CI 0.42–1.30; p = 0.30
Saitou et al.,
2010
PIO •62 Japanese patients
with T2DM
ACE I/D in intron
16
•MAF = 16.4%
IMT •NS
MTHFR C677T
•MAF = 16.4%
IMT •NS
(Continued)
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Table 2 | Continued
Study TZD
regimen
Study population
(inclusion criteria)
Gene/
polymorphism
Outcome Results
Himelfarb et al.,
2011
PIO 15, 30,
45, and
45mg QD
each 4
weeks (total
16 weeks)
•53 Brazilian patients
with T2DM
•No other hypoglycemic
agents or insulin
TNFA −308G>A
(rs11800629)
•MAF = 16.4%
OGTT-2 h glucose NS
Bone biomarkers •The A variant allele was associated
with lower tAPL levels, suggesting
reduced osteoblastic activity after PIO
therapy (p = 0.017)
IL6 −174G>C
(rs1800795)
•MAF = 13.9%
OGTT-2 h glucose •The minor allele was associated with
decreased OGTT-2 h glucose levels
(p < 0.05)
Bone biomarkers •NS
Chang et al.,
2011
PIO (n = 21)
or ROSI
(n = 247)
•268 Taiwanese patients
with T2DM
AQP2 rs296766
•CC = 203
•CT = 63
•TT = 2
Edema •The T variant allele was associated
with TZD-related peripheral edema.
•OR 2.89; 95% CI 1.61–5.17;
p = 0.0059
SLC12A1
rs12904216
•AA = 122
•AG = 106
•GG = 40
Edema •GG genotype was associated with
TZD-related peripheral edema
•OR 2.66; 95%CI 1.26–5.63; p = 0.011
Ruaño et al.,
2009
PIO (n = 33)
or ROSI
(n = 54) for
≥4 months
•87 patients with T2DM
•The use of other
anti-diabetics was
allowed
ADORA1
rs903361
•MAF = 33.0%
BMI •Presence of the variant allele was
associated with greater increase in
BMI
•Regression coefficient 3.4;
p = 0.0003; false discovery rate = 0.10
TZD, thiazolidinedione; PIO, pioglitazone; T2DM, type 2 diabetes mellitus; QD, once daily; MAF, minor allele frequency; HOMA-IR, Homeostasis Model of
Assessment-Insulin Resistance index; OGTT, oral glucose tolerance test; NS, not significant; IMT, carotid intima-media thickness; FG, fasting plasma glucose;
PPG, postprandial plasma glucose; OR, odds ratio; 95% CI, 95% confidence interval; ROSI, rosiglitazone.
FIGURE 2 | Change in fasting plasma glucose from baseline.
Comparison of PPARG p.Pro12Pro genotype vs. p.Pro12Ala carriers (Std diff
in means, standard difference in means; 95% CI, 95% confidence interval).
Two studies investigating response to PIO with respect to
ADIPOQ genotypes were identified in the literature search. These
studies were conducted in Chinese and Iranian populations (Li
et al., 2008; Namvaran et al., 2012). However, in the two stud-
ies, the only significant change in FG or A1C in response to PIO
was found with ADIPOQ C-11377G genotype in the study of
the Chinese population (Li et al., 2008; Namvaran et al., 2012).
The −11377 CC genotype patients had smaller reduction in A1C
than the minor G allele carriers (Li et al., 2008). Response to
ROSI was also previously studied with regard to the ADIPOQ
polymorphism. In Chinese T2DM patients treated with ROSI,
the wild-type −11377 CC genotype was associated with greater
reduction in FG, compared to the CG and GG genotypes (−34.2
vs. −9.7mmol/L, p = 0.001) (Sun et al., 2008). A definitive con-
clusion on this ADIPOQ polymorphism cannot be made due to
the lack of replication and because the direction of the associa-
tion was opposite with the ADIPOQC-11377G genotype between
the ROSI and PIO studies. Studies have shown that exercise
affects adiponectin concentrations (Gueugnon et al., 2012; Lee
et al., 2013). The Korean study reported that exercise increased
adiponectin levels irrespective of ADIPOQ polymorphisms (Lee
et al., 2013). Therefore, it may be possible that environmental
factors, such as exercise level, have a large impact and make it dif-
ficult to differentiate the effect of ADIPOQ polymorphisms on
response to PIO.
Adiponectin receptor 2 (ADIPOR2) is another gene studied
along with ADIPOQ polymorphism to explain PIO response vari-
ability. The ADIPOR2 gene is highly expressed at critical sites
involved in glucose metabolism and activation of this receptor is
known to increase fatty acid oxidation and adiponectin-mediated
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glucose utilization (Kadowaki et al., 2006; Namvaran et al., 2012).
However, in an Iranian population, ADIPOR2 G795A genotype
did not have any significant effect on FG and A1C in response
to PIO (Namvaran et al., 2012). No definitive conclusions can be
made from one study and the functionality of ADIPOR2 poly-
morphisms needs to be investigated further to understand the
involvement in PIO response. However, if any polymorphism in
ADIPOR2 can affect the functionality of the receptor, it may still
be possible that the polymorphism could have an influence on
response to PIO therapy.
The involvement of the resistin (RETN) gene in response to
PIO was studied in a Japanese population. Resistin is another
adipokine known to antagonize insulin (Osawa et al., 2004). The
role of RETN polymorphisms in T2DM or obese patients has
not been fully elucidated, but the RETN C-420G (rs1862513)
GG genotype was previously associated with T2DM susceptibil-
ity (Osawa et al., 2004; Ochi et al., 2007; Makino et al., 2009). Sp1
and Sp3 are transcription factors that bind to the DNA element,
if the −420 G allele is present, to enhance serum resistin con-
centrations via increased RETN promoter activity (Osawa et al.,
2004). The binding of Sp1/3 does not occur with the−420 C allele
(Osawa et al., 2004). One report suggested that TZD-mediated
PPARγ activation represses the expression of the resistin gene
by modulating Sp1 activity (Chung et al., 2005; Makino et al.,
2009). Makino et al. studied RETN C-420G polymorphism in
Japanese T2DM patients and found that the GG genotype was
associated with better FG and A1C reduction (Makino et al.,
2009). However, the reduction in A1C was observed only in
the replication cohort, and the significance with the FG reduc-
tion did not remain after adjustment for multiple testing. The
authors commented on differences in the patient characteristics
between the original and replication cohorts and that the sample
size might not have been adequate. It is reasonable to hypoth-
esize that patients with the GG genotype can recruit more Sp1
at baseline and therefore have more pronounced reduction in
serum resistin levels with PIO treatment. However, the effect of
this RETN C-420G SNP on PIO response needs to be further
investigated with the involvement of Sp1/3 signaling pathway.
The lipoprotein lipase (LPL) S447X polymorphism has been
studied with respect to PIO response. Lipoprotein lipase is the
rate-limiting enzyme for the breakdown of lipoproteins rich in
triglycerides (Groenemeijer et al., 1997). Lipoprotein lipase is syn-
thesized by and secreted from various parenchyma cells including
adipocytes, muscle cells, and macrophages and expression was
increased by PIO in a previous in vivo study (Bogacka et al., 2004;
Wang et al., 2007). Among more than 40 polymorphisms in LPL
gene, S447X is the most extensively studied polymorphism; it
causes a premature stop codon and the elimination of serine and
glycine at the C-terminal (Wang et al., 2007). Previous indepen-
dent studies reported an association of the S447X variant with
dyslipoproteinemia and coronary artery disease (Kuivenhoven
et al., 1997; Wang et al., 2007). This variant was investigated in
T2DM patients who received PIO and found that the response
rate (defined as >10% reduction in FG) to PIO was 0.54-fold
smaller in patients with the LPL S447X genotype, compared to
patients with the S447S genotype (Wang et al., 2007). Although
independent confirmation of this result is needed, LPL is another
candidate gene to be studied with response to PIO. In addition,
more functional studies are necessary to understand how this
polymorphism relates to glycemic control in humans.
Anti-atherosclerotic effect
The effect of genetic polymorphism on carotid atherosclerosis
progression has been studied in patients who received PIO. TZDs
were shown to improve lipid profiles, inflammation, coagulation,
and endothelial cell function, and PIO was shown to signifi-
cantly slow progression of carotid intima-media thickness (IMT)
(Saitou et al., 2010). In contrast to ROSI, which was associated
with an increased risk of MI, meta-analyses showed that PIO did
not increase the risk of MI and might have a benefit of decreas-
ing revascularization events (Nagajothi et al., 2008; Tannen et al.,
2013). A study investigated 99 candidate gene polymorphisms,
which were previously associated with atherosclerosis, diabetes
mellitus, hypertension, or dyslipidemia, among T2DM patients
treated with PIO (Saitou et al., 2010). Results for the angiotensin-
converting enzyme (ACE) gene and methylene-tetrahydrofolate
reductase (MTHFR) gene were reported, but the IMTwas not sig-
nificantly affected by polymorphisms in these two genes (Saitou
et al., 2010). However, they compared the results with patients
treated with diet alone. The IMT significantly increased in ACE
D allele carriers (average IMT from 0.802 ± 0.017 to 0.831 ±
0.017mm, p = 0.006; max IMT from 0.969 ± 0.023 to 0.998 ±
0.021mm, p = 0.05) and the MTHER 677T allele carriers (aver-
age IMT from 0.804 ± 0.012 to 0.839 ± 0.013mm, p = 0.001;
max IMT from 0.969 ± 0.023 to 1.010 ± 0.018mm, p = 0.007)
(Saitou et al., 2010). Thus, the study demonstrated that PIO
attenuated the increase in IMT irrespective of the genotypes.
Fracture risk
There is much concern with bone fractures as an ADR with
TZDs. Both ROSI and PIO are known to provoke bone loss, and
increased risks of fractures are reported, especially among women
with T2DM taking a TZD (Betteridge, 2011). The most common
sites of fractures are at distal limbs rather than at hips and spines
even though the reason for this localization of fractures is still
unclear (Betteridge, 2011; Cariou et al., 2012). PPARγ-mediated
actions on bone homeostasis are believed to be responsible for
these fractures. The activation of PPARγ was shown to pro-
mote osteoclastogenesis and suppress osteoblastogenesis, leading
to bone loss as the net effect (Wan, 2010). Tumor necrosis factor
α (TNFα) and interleukin-6 (IL-6) are inflammatory cytokines,
and their release is suppressed by PPARγ activation (Cariou et al.,
2012). TNFα differentiates human peripheral monocytes into
activated osteoclasts, so the reduced TNFα level can result in
inhibition of osteoclastogenesis (Hounoki et al., 2008).
TNFα and IL-6 are encoded by TNFA and IL6 genes respec-
tively, and the effect of TNFA and IL6 genotypes was studied in
T2DM patients who received PIO (Himelfarb et al., 2011). They
showed that TNFA –308A allele carriers had decreased mRNA
expression compared with those with the wild GG genotype
(Himelfarb et al., 2011). They also found that alkaline phos-
phatase, a biomarker for osteoblastic activity, was reduced in
response to PIO in TNFA −308A allele carriers with T2DM
(Himelfarb et al., 2011). IL6 −174C allele was associated with
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decreased OGTT-2h glucose but not with any bone metabolic
markers (Himelfarb et al., 2011). IL6 −174C allele was previously
associated with higher plasma levels of IL-6, but in this study,
mRNA expression did not differ by the IL6 genotype (Himelfarb
et al., 2011). Since replication is lacking and studies relating the
genotypes directly to the occurrence of fractures are missing, no
definitive conclusion can be made at this point.
Edema risk
Edema is a potential ADR from ROSI and PIO, and both TZDs
carry a FDA black box warning for CHF (Kung and Henry,
2012). The safety of TZDs for patients with New York Heart
Association class III or IV CHF is not established, and the use
of TZDs is contraindicated in this patient population (Kung and
Henry, 2012; Yau et al., 2013). The underlyingmechanism of both
edema and CHF appears to be fluid retention and expansion of
plasma volume (Kung and Henry, 2012). Two studies that ana-
lyzed the TZD-related edema risk were identified in the literature
search.
Twenty eight SNPs were genotyped from genes related to
sodium and water reabsorption (Chang et al., 2011). They found
that the AQP2 rs296766 T allele and SLC12A1 rs12904216 GG
genotype were associated with edema in T2DM patients treated
with a TZD (Chang et al., 2011). AQP2 gene codes aquaporins,
which function as a water channel on the apical membrane, pre-
dominantly in the collecting duct of the kidney (Knepper et al.,
1996). The AQP2 rs296766 SNP is located at the 3’ untranslated
region and may regulate mRNA stability (Chang et al., 2011).
SLC12A1 encodes apical Na-K-2CL cotransporter, NKCC2, which
plays an essential role in concentrating urine with the uptake of
CL− and K+ driven by the Na+ influx (Ji et al., 2008; Chang
et al., 2011). This transporter, coded by SLC12A1, is a target
of thiazides and furosemide, and genetic polymorphisms in this
gene were associated with blood pressure variation, Bartter syn-
drome, and response to loop diuretics (Ji et al., 2008; Chang
et al., 2011). The SLC12A1 rs12904216 SNP is located in intron
7, and the protein expression may be altered by this SNP (Chang
et al., 2011). Further studies are necessary to replicate the associ-
ation, to describe how AQP2 rs296766 and SLC12A1 rs12904216
SNPs affect the coded transporter function, and to clarify a pos-
sible existence of other functional polymorphisms in linkage
disequilibrium.
The other study genotyped 384 SNPs in genes involved in car-
diovascular and metabolic pathways (Ruaño et al., 2009). The top
five polymorphisms possibly associated with edema were: neu-
ropeptide Y (NPY) rs1468271 (p = 0.006), glycogen synthase 1
(GYS1) rs2287754 (p = 0.013), chemokine C-C motif ligand 2
(CCL2) rs3760396 (p = 0.015), oxidized low density lipoprotein
receptor 1 (OLR1) rs2742115 (p = 0.015), and growth hormone
releasing hormone (GHRH) rs6032470 (p = 0.023) (Ruaño et al.,
2009). However, none of the polymorphisms associated with
edema after accounting for multiple comparisons.
The other factors related to edema were women sex and
older age (Chang et al., 2011). According to these findings and
the pharmacogenetic data, the investigators developed a simple
point system to predict the likelihood of TZD-related edema
based on age, sex, and AQP2 rs296766 and SLC12A1 rs12904216
genotypes (Chang et al., 2011). Although this point system needs
to be validated in an independent cohort, the development of
a simple scoring system is a good example of making pharma-
cogenetic information more useful and meaningful in clinical
practice.
Increase in body mass index (BMI)
Besides the occurrence of edema, Ruaño et al. (2009) investi-
gated possible associations of the 384 SNPs from cardiovascular
and metabolic pathways with change in BMI. Weight gain is
one of the common ADRs of TZDs. In a PIO monotherapy
trial, patients gained 2.82 kg after the treatment of 45mg PIO
for 26 weeks while weight loss was observed in a placebo group
(Kung and Henry, 2012). The weight gain appears to be dose-
dependent, and the mechanism is not only related to the fluid
retention but also increase in subcutaneous fat depots (Kung
and Henry, 2012). The top five polymorphisms possibly associ-
ated with change in BMI were: adenosine A1 receptor (ADORA1)
rs903361 (0.0003), pyruvate kinase (PKM2) rs2856929 (p =
0.002), ADIPOR2 rs7975375 (p = 0.007), uncoupling protein 2
(UCP2) rs660339 (p = 0.008), and apolipoprotein H (APOH)
rs8178847 (p = 0.010) (Ruaño et al., 2009). After adjustment
for multiple comparisons, rs903361, a SNP located in intron 2
of the ADORA1 gene, was significantly associated with increase
in BMI (Ruaño et al., 2009). The adenosine A1 receptor is a
G-protein-coupled receptor highly expressed in adipose tissue
and activation of this receptor leads to inhibition of lipolysis
(Dhalla et al., 2009). How the rs903361 SNP affects the func-
tionality of the receptor is unknown and the association of
this SNP with BMI must still be replicated in an independent
cohort.
CONCLUSIONS
Clinically relevant variability in pioglitazone response has been
demonstrated, but the underlying factors contributing to variabil-
ity are not well-understood. This hypothesis article summarizes
current evidence on pioglitazone pharmacogenomics; current
data suggest that genetic variation is indeed an important factor
contributing to pioglitazone response. Thus, we posit a strat-
egy incorporating pharmacogenomic information may provide a
more rational approach to achieve optimal outcomes. According
to PharmGKB (https://www.pharmgkb.org), CYP2C8*3 is the
only genetic variant annotated for PIO treatment as level 3
evidence, which was defined as “annotation for a variant-drug
combination based on a single significant (not yet replicated) or
annotation for a variant-drug combination evaluated in multi-
ple studies but lacking clear evidence of an association”(Whirl-
Carrillo et al., 2012). However, more studies investigating genetic
effect on PIO therapy are now available. In this article, the PIO
pharmacogenetic evidence to date is summarized. The genes
investigated for sources of variability in PIO PK are CYP2C8
and SLCO1B1. The variant allele CYP2C8*3 is associated with
higher PIO clearance, which results in reduced exposure to PIO in
carriers of this allele. The alteration in PIO PK has clinical impli-
cations, and the relevant consequences with drug interaction are a
concern. Thus, if an inhibitor, inducer or substrate of CYP2C8 is
to be administered with PIO in known CYP2C8∗3 carriers, closer
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monitoring may be warranted. For future studies of PIO, CYP2C8
genotyping is recommended to better understand the variabil-
ity in response to PIO and to interpret data more clearly when
CYP2C8∗3 carriers are present in the study. This may be espe-
cially important because of racial differences in CYP2C8∗3 allele
frequency. The ∗3 variant has been the focus of clinical PK stud-
ies with PIO, but the functionality of other CYP2C8 variant alleles
need to be further determined preferably in vivo because the dis-
crepancy between in vitro and in vivo data have been shown with
CYP2C8 activity. In contrast to CYP2C8, there is currently no evi-
dence to suggest that genetic variation in drug transporters affects
PIO disposition.
The genetic polymorphism most widely studied to better
understand variability in PIO PD is PPARG p.Pro12Ala. T2DM
patients with PPARG p.Pro12Ala variant are likely to have bet-
ter glycemic response with PIO. Thus, the PPARG p.Pro12Ala is
a promising polymorphism and one that should be included in
clinical models developed to predict a patient’s response based
on genotype. However, this polymorphism alone is unlikely to
explain all of the variability seen among patients. Consequently,
other genetic variants as well as clinical factors must be con-
sidered. Indeed, several polymorphisms were identified in other
genes related to PIO pathways. However, it is difficult to make any
firm conclusions, based on single studies reporting a significant
association, especially if it is not known how the polymorphism
affects the functionality of the coded protein. Similarly, the identi-
fied polymorphism may merely be in linkage disequilibrium with
the true functional variant. Therefore, the data must be inter-
preted with caution. Validation or replication of the finding is
necessary before the pharmacogenetic knowledge can be applied
to patient care. To better explain the variability in response,
gene-gene and gene-environment interactions should also be
considered.
Based on current evidence, we propose that pharmacoge-
nomics may provide an important tool to individualize piogli-
tazone therapy. For example, developing a scoring system that
incorporates both clinical and genetic factors may provide more
clinical utility and make the pharmacogenetic evidence more
accessible to clinicians who are unfamiliar with this field. This is
important because the data from several genes suggest PIO phar-
macogenomics has the potential to be an important means to
better optimize therapy in patients with T2DM.
SUPPLEMENTARY MATERIAL
The Supplementary Material for this article can be found
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